STOCKS TELEGRAPH

Tag: Innate

  • Innate Pharma (IPHA) Shares Rally In Pre-Hour Trading After Key FDA Decision

    Innate Pharma (IPHA) Shares Rally In Pre-Hour Trading After Key FDA Decision

    Innate Pharma S.A. (NASDAQ: IPHA) stock is on a sharp increase today after a major regulatory notification. IPHA stock was trading at $2.48 as of the latest pre-market check with a 27.8% rise. The company’s most recent medication research achievement is the cause of this encouraging market shift.

    Lacutamab Receives FDA Breakthrough Therapy Designation

    Innate Pharma announced that their experimental medication, lacutamab, has been awarded Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA). Adult patients with relapsed or refractory (r/r) Sézary Syndrome (SS) who have had at least two previous systemic medications, such as mogamulizumab, are being treated with an anti-KIR3DL2 cytotoxicity-inducing antibody.

    Based on encouraging results from a Phase 1 research and the Phase 2 TELLOMAK trial, which showed lacutamab’s potent effectiveness and good safety profile in patients who had previously received mogamulizumab, the designation was made. The findings demonstrate lacutamab’s potential as a cutting-edge treatment choice for individuals with advanced Sézary syndrome.

    Taking Care of an Emergency Medical Need

    The FDA’s Breakthrough Therapy Designation of lacutamab highlights the drug’s potential to provide a significant improvement over current therapies. In order to accelerate the development of lacutamab, Innate Pharma expressed excitement about collaborating closely with the FDA. With the ultimate objective of providing patients with a safer and more effective treatment alternative, the firm sees this certification as a critical step in advancing its strategy for the medicine.

    Investing Possibilities

    IPHA is currently rated as “Undervalued” on our ST screener suggesting potential investment opportunities within the Biotechnology sector. Interested parties are encouraged to explore peer stocks with similar or greater growth prospects through our ST screener link.

    Upcoming Developments

    The FDA granted lacutamab Fast Track status in 2019 for the treatment of relapsed or refractory Sézary syndrome. Moreover, it also succeeded to receive PRIME designation from the European Medicines Agency (EMA) next year. As it moves closer to a confirming Phase 3 trial in cutaneous T-cell lymphoma (CTCL), Innate Pharma (IPHA) is still in compliance with regulatory bodies and is actively looking for a development partner to help with its work.

  • Innate Pharma S.A. (IPHA) Stock Surges During After Hours Trading Ahead of Progress Update Meeting

    Innate Pharma S.A. (IPHA) stock prices were down by a marginal 1.87% as of the market closing on June 16th, 2021, bringing the price per share down to USD$3.9350. After-hours trading saw the stock rally by an impressive 10.55%, bringing it up to USD$4.40.

    Disclosure of New Data

    The company announced on June 10th, 2021 that it will present the most recent preclinical data from it’s next-gen, proprietary, multi-specific NK cell engager platform, ANKET. The presentation will be held at the Federation of Clinical Immunology Societies (FOCIS) meeting, showcasing Antibody-based NK cell Engager Therapeutics.

    FOCIS Presentation

    The presentation will see IPHA share new data from its tetra-specific ANKET molecule, which is the first NK cell engager technology to engage both NKp46 and CD16, the former of which is a tumor antigen and the latter a cytokine (IL-2 variant) in a single molecule. This newest development makes use of the advantages of harnessing NK cell effector functions against cells affected by cancer. It also facilitates the provision of the proliferation and activation The data set generated is founded on the company’s existing tri-specific NK cell engager technology. This technology has a proven track record of potent NK cell activation, cytotoxicity, and efficient management of tumor growth in preclinical models.

    Scope of ANKET

    Preclinical studies demonstrated the ability of in vitro tetra-specific ANKET to induce human NK cell proliferation, cytokine production, and cytolytic activity against cancer cells expressing the targeted antigen. Tetra-specific ANKET was also reported to have demonstrated in vivo anti-tumor efficacy in several tumor models, which allows for the regression of exiting tumors. Control of metastasis is also facilitated, with its associations with increased NK cell infiltration, and cytokine and chemokine production at the tumor site. The treatment also exhibited the pharmacodynamic effect, low systemic cytokine release, and a manageable safety profile in non-human primates.

    IPH6101

    The company’s leading ANKET asset is IPH6101, which has exhibited anti-tumor activity in preclinical models, including, but not limited to, facilitating pharmacokinetic pharmacodynamic and safety data in preliminary non-human primate studies. January 2021 saw the progression of the program into IND-enabling studies, with a recently announced research collaboration facilitating a second research program.

    Future Outlook for IPHA

    Armed with the development of their proprietary ANKET NK cell engager platform, IPHA is poised to continue its trajectory of success. The company is keen to continue working towards the commercialization and proliferation of their technology to usher in further gains. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.